Bostancı, ÖzgürSayın, PınarKızıltan, RemziAlgül, ŞerminAydın, Mehmet AkifKemik, Özgür2023-01-152023-01-152022Bostancı, O., Sayın, P., Kızıltan, R., Algül, S., Aydın, M. A., & Kemik, O. (2022). B7-H3 : A useful emerging diagnostic marker for colon cancer. BioMed Research International, 2022.https://hdl.handle.net/20.500.12939/3184Background: Colon cancer is the second most common malignancy causing the majority of cancer-related deaths. B7-H3 concentrations have drawn major interest as possible diagnostic biomarkers of cancer. The aim of this study was to measure the preoperative serum B7-H3 levels and to determine those that are replaced in colon cancer. Method: We measured preoperative serum B7-H3 concentrations of 90 patients aged 57-69 years diagnosed with colon cancer and 50 age-matched healthy individuals. B7-H3 levels were determined using the sandwich enzyme-linked immunosorbent assay (ELISA). Patients were categorized by stage based on the TNM staging system, and the serum levels of B7-H3 were compared between patients with different TNM stages. Result: No statistically significant difference was found between the patient and control groups in terms of age and gender. Preoperative serum B7-H3 levels were statistically significantly higher in patients with colon cancer than in the healthy group (p < 0.001). Preoperative serum B7-H3 concentration of the stage IV patients was significantly higher than those of the patients with stage I and stage II disease. In addition, higher serum B7-H3 levels were associated with lymph node status and distant metastasis in colon cancer. Conclusion: We showed that B7-H3 is highly expressed in colon cancer and can be used as a candidate diagnostic biomarker and a potential target in colon cancer in future.eninfo:eu-repo/semantics/openAccessColon CancerB7-H3 ConcentrationsArticle2-s2.0-85145645651Q1WOS:000917292900005Q3